FDA approves Opdivo Qvantig, an injectable cancer drug, set to debut in January.

The FDA has approved an injectable version of Bristol Myers Squibb's cancer drug, Opdivo, called Opdivo Qvantig. This new form is more convenient for patients and will be available in early January at the same price as the current intravenous version. It is approved for all previously approved adult solid tumor uses. The approval was based on a study showing the injectable form is as effective as the IV version for advanced kidney cancer patients.

3 months ago
7 Articles